Programme
Speakers
Profile
KEYNOTE SPEAKER
Mr. How ti-hwei
Country President, AstraZeneca
Keynote Talk: Introduction to Singapore's Bio-Pharmaceuticals
Ti-Hwei is the Country President of AstraZeneca Singapore, a global, science-led pharmaceutical company, focused on the discovery, development and commercialisation of life-changing prescription medicines. He also serves as the President of the Singapore Association of Pharmaceutical Industries (SAPI), and the Chair of the European Chamber of Commerce (EuroCham) Healthcare Committee. He is also a member of the NUS Pharmacy Programme Advisory Board, and the Ngee Ann Polytechnic Life Sciences & Chemical Technology Advisory Committee. A Singapore national, Ti-Hwei holds a Bachelor of Science (Pharmacy) with Honours, and an MBA from the National University of Singapore. He completed his pre-registration Pharmacist training in National University Hospital before venturing into the private sector. Ti-Hwei has had more than 20 years of Commercial experience across the Pharmaceutical & FMCG industries and has spent the last 7 years in various General Management roles. Outside of Singapore, his career has seen him lived and worked in Thailand, the Philippines, Vietnam and Malaysia. He currently resides in Singapore with his wife and 2 teenage sons. He stays active playing tennis and mountain-biking.
PANEL DISCUSSION
Challenges in the Singapore Bio-Pharmaceutical Landscape
LET'S
DISCUSS
The bio-pharmaceutical industry is a maturing industry, now challenged with more generic competition and increasing regulatory expectations from governing bodies across the world. As a result, processes from the research all the way to the healthcare front are pursuing leaner, more efficient procedures. The question is, how does this pursuit affect the overall health of the landscape? In the opening panel discussion for Pheature 2019, we will be exploring the challenges in Singapore bio-pharmaceutical landscape as a case study.
​
Discussion Panel (from left to right):
-
Mr How Ti Hwei (Moderator)
-
Dr Keith Carpenter (Executive Director, A*Star Singapore)
-
Dr Alireza Hosseini (Chief Operating Officer, Singapore Biotech
TRACK SPEAKERS
Pharma 4.0: What's in it for the next generation?
The opening panel will give the audience an overview of what the challenges the current biopharmaceutical industry is facing, and how the industry intends to move forward in the coming years. Through this panel discussion, get in-depth analysis from industry leaders on the trends and behaviours you should be looking out for from the research to manufacturing and finally healthcare front.
Mr Lee Hong Ping, Director of Sales (ATF)
Exyte Singapore
​
Hong Ping has over 24 years of working experience in the Electronics Manufacturing, Advanced Technologies, Life Science, Chemical process industries and in Facility Building design, construction, project management, general management, sales, marketing & business development. In the last 15 years, Hong Ping has worked for multi-national corporations providing consulting, engineering and construction services to the manufacturing, process, industrial and commercial sectors. His responsibilities included Strategic Planning, Business Development, Sales and Marketing for Singapore and the South East Asian countries.
Mr Ming Chua, Commissioner
Halfmann Goetsch Partner
​
Managing Director of HGP Asia (an NNIT Company) with a demonstrated history of working in the management consulting industry. Skilled in Medical Devices, Biotechnology, Life Sciences, Commissioning, and Validation. Strong professional with a Bachelor of Engineering focused in Biochemical Engineering from University College London, U. of London.
Dr Kelvin Ng Songyu, Head, Strategic Innovation
Bioprocessing Technology Institute
​
Dr Kelvin Ng is the Head of Strategic Innovation at the Bioprocessing Technology Institute, under the Agency for Science, Technology & Research (A*STAR) of Singapore. In this role, he targets biotech industries ranging from biosimilars, cell/gene therapies, to cultured meat. In another role that serves A*STAR at large, he supports the scientific, business, and regulatory aspects of alternative proteins, in the execution of the S$144-million Singapore Food Story. Previously in industry, Kelvin established cGMP-compliant workflows to scale up the production of human stem cells in preparation for regulatory filings. He also pioneered a new product line (now launched) and proprietary technologies for the exosome market. A bioengineer by training, Kelvin obtained his PhD at the joint Health Sciences & Technology program between Massachusetts Institute of Technology and Harvard Medical School.
MR MiNG CHUA
Commissioner
Halfmann Goetsch Partner
Presentation Topic: Pharma Professional v4.0
An introduction to Pharma 4.0 and the implications of digital transformation in the Life Science market place in redefining job scopes, core skills as well as emergence of NNIT-HGPs
Mr Willson deng
CEO
Arcstone Pte. Ltd
Presentation Topic: Digital information in the Bio-Pharma Industry
A sharing on the case studies that involve data analytics, equipment maintenance through preventative and predictive maintenance and lastly discrete event simulations for the bio-pharma industry
Mr Hugh McKee
Senior Process Consultant
PM Group
Presentation Topic: Contamination Control and Cleaning Challenges
Exploring case studies involving 4.0 and how challenges of the design, manufacturing and engineering are tackled with the changing digital revolution.
JULIAN KOO
Presentation Topic: Healthcare Without Walls: Jaga Me
Jaga-Me is a health technology company with the vision of creating a future of healthcare without walls. Through a web and app platform, Jaga-Me personalizes the medical services, products, and nutrition, directly to patients at home. Trusted by the largest public hospitals in Singapore, Jaga-Me has enabled over 2,000 patients to be cared for in the comfort and safety of home, without being confined to the walls of a care institution.